Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis ...Middle East

A greater proportion of patients achieved 100 percent improvement in skin clearance at the highest dose level tested compared to placebo, at week 16 Phase 3 clinical development in moderate-to-severe plaque psoriasis is planned SPRING HOUSE, Pa., July 4, 2023 /PRNewswire/ -- The Janssen...

Hence then, the article about janssen announces positive topline results for jnj 2113 a novel first and only oral il 23 receptor antagonist peptide in development for moderate to severe plaque psoriasis was published today ( Tuesday 04/07/2023 - 09:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis )

Also on site :

• Thriller! Rylan Sevilla’s fourth-quarter heroics lift No. 17 Dougherty Valley past No. 9 Bishop O’Dowd
• Nordstrom Rack Has a 'Gorgeous' 5-Piece Tennis Bracelet Set on Sale for Just $20: 'The Sparkle Is Unreal'
• CES 2026: Guangfan Technology Reveals Lightwear, Introducing World's First Vision-Enabled AI Earphones